Page 8 - ப்ராஸ்டேட் புற்றுநோய் பரிசோதனை சந்தை அளவு பகுப்பாய்வு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ப்ராஸ்டேட் புற்றுநோய் பரிசோதனை சந்தை அளவு பகுப்பாய்வு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ப்ராஸ்டேட் புற்றுநோய் பரிசோதனை சந்தை அளவு பகுப்பாய்வு Today - Breaking & Trending Today

Researchers analyze overall survival rate of prostate cancer patients treated with melatonin


Researchers analyze overall survival rate of prostate cancer patients treated with melatonin
Oncotarget recently published Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment which reported that a retrospective study included 955 patients of various stages of prostate cancer who received combined hormone radiation treatment from 2000 to 2019. Comprehensive statistical methods were used to analyze the overall survival rate of PCa patients treated with melatonin in various prognosis groups.
The overall survival rate of PCa patients with favorable and intermediate prognoses treated or not treated with melatonin was not statistically significantly different.
In the poor prognosis group, the median overall survival in patients taking the drug was 153.5 months versus 64.0 months in patients not using it. ....

Vladimirn Anisimov , Emily Henderson , Anisimov Research Team , Nn Petrov National Medical Research Center , Oncotargetresearch Paper , National Medical Research Center , Prostate Cancer , எமிலி ஹென்டர்சன் , ந் பெட்ரோவ் தேசிய மருத்துவ ஆராய்ச்சி மையம் , தேசிய மருத்துவ ஆராய்ச்சி மையம் , ப்ராஸ்டேட் புற்றுநோய் ,

HKBU and CUHK jointly develop Spermine Risk Score for diagnosis of prostate cancer


HKBU and CUHK jointly develop Spermine Risk Score for diagnosis of prostate cancer
Feb 8 2021
Researchers from Hong Kong Baptist University (HKBU) and the Faculty of Medicine at The Chinese University of Hong Kong (CU Medicine) have jointly developed the Spermine Risk Score which, coupled with the use of a urine test, provides a non-invasive and more reliable method for the diagnosis of prostate cancer. In a study conducted by the researchers, about 37% of the patients, who were ultimately found to have no prostate cancer, can avoid undergoing a prostate biopsy procedure. The findings have just been published in the scientific journal ....

Hong Kong , University Of Hong Kong , Hong Kong General , Peter Chiu Ka Fung , Gary Wong Ka Leung , Emily Henderson , Department Of Chemistry , Chinese University Of Hong Kong Cu Medicine , Head Of The Department Chemistry , Hong Kong Baptist University , Division Of Urology , Department Of Surgery , Chinese University , Spermine Risk Score , Prostate Cancer , Health Protection , Professor Gary Wong Ka Leung , Professor Ng Chi Fai , Associate Professor , Spermine Risk Scores , Cancer Diagnosis , Blood Test , Prostate Biopsy , Urine Test , ஹாங் காங் , பல்கலைக்கழகம் ஆஃப் ஹாங் காங் ,